Sakar Healthcare (NSE:SAKAR) Short-Term Debt: ₹240 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SAKAR Sakar Healthcare Ltd NSE:SAKAR
61 GF Score
Price ₹875.95
GF Value ₹558.80
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sakar Healthcare Short-Term Debt?

Sakar Healthcare NSE:SAKAR -4.61% 61 Short-Term Debt is ₹240 Mil as of Mar. 2026. GuruFocus rates NSE:SAKAR with a GF Score™ of 61/100 and a GF Value™ of ₹558.80 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Sakar Healthcare's Short-Term Debt for the quarter that ended in Mar. 2026 was ₹240 Mil.

Sakar Healthcare's quarterly Short-Term Debt declined from Sep. 2025 (₹266 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹240 Mil).

Sakar Healthcare's annual Short-Term Debt increased from Mar. 2024 (₹244 Mil) to Mar. 2025 (₹328 Mil) but then declined from Mar. 2025 (₹328 Mil) to Mar. 2026 (₹240 Mil).

Sakar Healthcare Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Sakar Healthcare Short-Term Debt Related Terms

Sakar Healthcare Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Sakar Healthcare's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sakar Healthcare Short-Term Debt Chart

Sakar Healthcare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 78.55 209.50 243.97 327.81 239.51

Sakar Healthcare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 327.81 0.00 266.06 0.00 239.51
NSE:SAKAR
61GF Score
Sakar Healthcare Ltd NSE:SAKAR
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ₹240 Mil mean?
Sakar Healthcare (NSE:SAKAR) has a Short-Term Debt of ₹240 Mil as of Mar. 2026.
Is Sakar Healthcare's Short-Term Debt too high?
Sakar Healthcare's current Short-Term Debt is ₹240 Mil. Overall, Sakar Healthcare has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sakar Healthcare's Short-Term Debt compare to ZTS?
Sakar Healthcare's Short-Term Debt of ₹240 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Sakar Healthcare's current Short-Term Debt is ₹240 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sakar Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sakar Healthcare (NSE:SAKAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹558.80, compared to a current price of ₹875.95 — trading 56.8% above its estimated fair value. The current Short-Term Debt is ₹240 Mil. Sakar Healthcare's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Sakar Healthcare (NSE:SAKAR), the current Short-Term Debt is ₹240 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sakar Healthcare (NSE:SAKAR) Overvalued in 2026?

Based on GuruFocus' analysis, Sakar Healthcare stock appears to be overvalued. The current stock price of ₹875.95 is trading 56.8% above its estimated GF Value™ of ₹558.80. GuruFocus considers Sakar Healthcare to be Significantly Overvalued.

Key valuation signals for NSE:SAKAR:

  • Short-Term Debt: ₹240 Mil
  • GF Value™: ₹558.80 vs. price of ₹875.95 (56.8% above fair value)
  • GF Score™: 61/100 with 6 warning signs

No single metric tells the full story. See the NSE:SAKAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sakar Healthcare Business Description

Address 406, Silver Oaks Comm. Complex, Opposite Arun Society, Paldi, Ahmedabad, GJ, IND, 382 007
Sakar Healthcare Ltd is engaged in manufacturing Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. The company offers its products to Sri Lanka, the Philippines, Vietnam, Cambodia, Sudan, Myanmar, Mauritius, Costa Rica, Panama, El Salvador and Paraguay.
61GF Score

Get the complete analysis for NSE:SAKAR

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹875.95
Price
₹558.80
GF Value